UTHR Profile
United Therapeutics Corporation, headquartered in Silver Spring, Maryland, is a prominent biotechnology firm dedicated to developing and commercializing innovative therapies for patients grappling with chronic and life-threatening diseases across global markets.
The company's portfolio includes several commercially available therapies. Remodulin is designed to alleviate symptoms associated with exercise in patients suffering from pulmonary arterial hypertension (PAH). Tyvaso, an inhaled prostacyclin analogue, enhances exercise capacity in PAH patients and those with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Orenitram, available in tablet form, also improves exercise capacity in PAH patients.
United Therapeutics continues to expand its pipeline with promising products under development. These include Tyvaso DPI, a dry powder inhalation variant of Tyvaso, and Remunity Pump, a compact, durable pump designed for convenient administration. The company is also advancing innovative therapies like RemoPro and Ralinepag for PAH treatment, Aurora-GT for gene therapy targeting lung blood vessel regeneration, and Tyvaso PERFECT and TETON studies focusing on World Health Organization (WHO) Group 3 pulmonary hypertension linked with chronic obstructive pulmonary disease (PH-COPD).
United Therapeutics collaborates extensively through licensing agreements to enhance its product offerings. Partnerships with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. underscore its commitment to innovation and expanding treatment options for patients worldwide.
Established in 1996, United Therapeutics Corporation remains at the forefront of biotechnology, driven by a mission to meet critical medical needs through cutting-edge research, development, and commercialization of transformative therapies.
|
